The short version of quality control fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-16 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
=== Chemical === Darmstadtium is the eighth member of the 6d series of transition metals, and should be much like the platinum group metals. Calculations on its ionization potentials and atomic and ionic radii are similar to that of its lighter homologue platinum, thus implying that darmstadtium's basic properties will resemble those of the other group 10 elements, nickel, palladium, and platinum. Prediction of the probable chemical properties of darmstadtium has not received much attention recently. Darmstadtium should be a very noble metal. The predicted standard reduction potential for the Ds2+/Ds couple is 1.7 V. Based on the most stable oxidation states of the lighter group 10 elements, the most stable oxidation states of darmstadtium are predicted to be the +6, +4, and +2 states; however, the neutral state is predicted to be the most stable in aqueous solutions. In comparison, only platinum is known to show the maximum oxidation state in the group, +6, while the most stable state is +2 for both nickel and palladium. It is further expected that the maximum oxidation states of elements from bohrium (element 107) to darmstadtium (element 110) may be stable in the gas phase but not in aqueous solution. Darmstadtium hexafluoride (DsF6) is predicted to have very similar properties to its lighter homologue platinum hexafluoride (PtF6), having very similar electronic structures and ionization potentials. It is also expected to have the same octahedral molecular geometry as PtF6.
A 2004 meta-analysis of randomised controlled clinical trials that compared benzodiazepines to zopiclone or other Z drugs such as zolpidem and zaleplon has found few clear and consistent differences between zopiclone and the benzodiazepines in sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, rebound insomnia, and daytime alertness.
Chiral molecules have two forms (at each point of asymmetry), which differ in their optical characteristics: The levorotatory form (the (−)-form) will rotate counter-clockwise on the plane of polarization of a beam of light, whereas the dextrorotatory form (the (+)-form) will rotate clockwise on the plane of polarization of a beam of light. The two forms, which are non-superposable when rotated in 3-dimensional space, are said to be enantiomers. The notation is not to be confused with D and L naming of molecules which refers to the similarity in structure to D-glyceraldehyde and L-glyceraldehyde. Also, (R)- and (S)- refer to the chemical structure of the molecule based on Cahn–Ingold–Prelog priority rules of naming rather than rotation of light. R/S notation is the primary notation used for +/- now because D and L notation are used primarily for sugars and amino acids. Racemization occurs when one pure form of an enantiomer is converted into equal proportion of both enantiomers, forming a racemate. When there are both equal numbers of dextrorotating and levorotating molecules, the net optical rotation of a racemate is zero. Enantiomers should also be distinguished from diastereomers which are a type of stereoisomer that have different molecular structures around a stereocenter and are not mirror images. Partial to complete racemization of stereochemistry in solutions are a result of SN1 mechanisms. However, when complete inversion of stereochemistry configuration occurs in a substitution reaction, an SN2 reaction is responsible.
The advent of global decolonisation and the subsequent rise in prominence of the Soviet Union among several newly independent African states was viewed with wariness by the South African government. National Party politicians began warning it would be only a matter of time before they were faced with a Soviet-directed insurgency on their borders. Outlying regions in South West Africa, namely the Caprivi Strip, became the focus of massive SADF air and ground training manoeuvres, as well as heightened border patrols. A year before SWAPO made the decision to send its first SWALA recruits abroad for guerrilla training, South Africa established fortified police outposts along the Caprivi Strip for the express purpose of deterring insurgents. When SWALA cadres armed with Soviet weapons and training began to make their appearance in South West Africa, the National Party believed its fears of a local Soviet proxy force had finally been realised. The Soviet Union took a keen interest in Africa's independence movements and initially hoped that the cultivation of socialist client states on the continent would deny their economic and strategic resources to the West. Soviet training of SWALA was thus not confined to tactical matters but extended to Marxist–Leninist political theory, and the procedures for establishing an effective political-military infrastructure. In addition to training, the Soviets quickly became SWALA's leading supplier of arms and money.
Sources: en.wikipedia.org
== Effect on sleep architecture == In a small study of 14 subjects, ibutamoren dosed at 25 mg/day at bedtime was shown to increase rapid eye movement sleep by 20% and 50% in young and older subjects respectively. Treatment with ibutamoren also resulted in an approximate 50% increase in slow-wave sleep in young subjects.
=== Notable members === Ebenezer Allen – militia member (lieutenant) (Ethan Allen's cousin) Ethan Allen – militia leader (general) Ira Allen – militia leader, and the founder of the University of Vermont (Ethan Allen's brother) Remember Baker – militia member (captain) (Ethan Allen's cousin) John Fassett Jr. – Vermont Supreme Court Justice, 1778–1786, diarist who chronicled the Green Mountain Boys' 1775 expedition to Canada. David Fay – Vermont Supreme Court Justice, adjutant general of the Vermont Militia Jonas Fay – regimental surgeon and political leader of early Vermont Jonas Galusha – militia leader (captain), future governor of Vermont Joab Hoisington – militia leader, Hoisington's Rangers (major), served in the French-Indian War, and participated in the Battle for Crown Point Matthew Lyon – militia member (second lieutenant), and future congressman David Robinson – son of Captain Samuel Robinson, a founder of Bennington Moses Robinson – colonel in Vermont Militia during American Revolution, 2nd governor of Vermont Republic, one of the first two senators from Vermont. Thomas Rowley – poet, militia member, and spokesman, known as the "Bard of the Green Mountains" who "Set the Hills on Fire". Elishama Tozer – militia member (lieutenant) Seth Warner – militia leader (colonel)
==== Organically sourced micronutrients ==== Micronutrients can be sourced from organic fertilizers as well. For example, composted pine bark is high in manganese and is sometimes used to fulfill that mineral requirement in conventional hydroponic solutions. To satisfy requirements for National Organic Programs, pulverized, unrefined minerals (e.g. Gypsum, Calcite, and glauconite) can also be added to satisfy a plant's nutritional needs.
== Signaling pathway == The essential function of the TCR complex is to identify specific bound antigen derived from a potentially harmful pathogen and elicit a distinct and critical response. At the same time it has to ignore any self-antigen and tolerate harmless antigens such as food antigens. The signal transduction mechanism by which a T cell elicits this response upon contact with its unique antigen is termed T-cell activation. Upon binding to pMHC, the TCR initiates a signaling cascade, involving transcription factor activation and cytoskeletal remodeling resulting in T-cell activation. Active T cells secrete cytokines, undergo rapid proliferation, have cytotoxic activity and differentiate into effector and memory cells. When the TCR is triggered, T cells form an immunological synapse allowing them to stay in contact with the antigen presenting cell for several hours. On a population level, T-cell activation depends on the strength of TCR stimulation, the dose–response curve of ligand to cytokine production is sigmoidal. However, T-cell activation on a single cell level can be characterized by a digital switch-like response, meaning the T cell is fully activated if the stimulus is higher than a given threshold; otherwise the T cell stays in its non-activated state. There is no intermediate activation state. The robust sigmoid dose-response curve on population level results from individual T cells having slightly different thresholds. T cells need three signals to become fully activated.
A 2023 study by Singh et al using higher resolution markers than previous studies found that there was higher gene flow from South India to the Sinhalese than from North India, with the Sinhalese sharing the highest Identity by descent with Tamils, especially the Piramalai Kallars, compared to the other Indian populations studied. The study also found heightened sharing with the Maratha of India, consistent with a West Eurasian contribution .This excess sharing of segments suggests common roots of Sinhala with the Marāṭhā corroborating the linguistic hypothesis of Lazarus Geiger, Ralph Lilley Turner, and George van Driem. The total Sinhalese sample size used was 9 individuals. A 2025 study by Aragon et al again found that the Sinhalese were genetically closer to populations from South India than to populations from North India. The study also failed to find high genetic affinities and allele sharing with North Indian populations. The study collected 35 Sinhalese samples from multiple cities (Galle, Anuradhapura, Kandy, Matale, Ratnapura, Kurunegala, Colombo, Kalutara, and Gampaha) in order to build a more representative picture.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.